SRR975598
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.490
- OXIDATIVE_PHOSPHORYLATION+0.450
- CHOLESTEROL_HOMEOSTASIS+0.370
- E2F_TARGETS+0.330
- MYC_TARGETS_V1+0.330
- GLYCOLYSIS+0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- DNA_REPAIR+0.260
- FATTY_ACID_METABOLISM+0.250
- UV_RESPONSE_UP+0.230
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- UV_RESPONSE_DN-0.390
- IL6_JAK_STAT3_SIGNALING-0.380
- INFLAMMATORY_RESPONSE-0.350
- ANGIOGENESIS-0.330
- INTERFERON_GAMMA_RESPONSE-0.310
- TGF_BETA_SIGNALING-0.310
- KRAS_SIGNALING_UP-0.280
- PROTEIN_SECRETION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.902 |
| 2 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.887 |
| 3 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.872 |
| 4 | f20785b9-991d-4b87-8ba7-ca32373f1996 | — | — | 0.872 |
| 5 | s0102872 | — | — | 0.861 |
| 6 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.847 |
| 7 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.846 |
| 8 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.845 |
| 9 | SRR17866857 | — | — | 0.842 |
| 10 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |